Page 1

AbCellera NEWS RELEASE AbCellera Reports Q3 2021 Business Results 11/9/2021 ● • Total revenue of $ 6 million , compared to $ 9 million in Q3 2020 Nine program starts in the quarter bringing cumulative total to 69 , up 35 % from Q3 2020 Net loss of ( $ 0.08 ) per share ( basic and diluted ) compared to a net loss of ( $ 0.02 ) per share ( basic and diluted ) in Q3 2020 ● VANCOUVER , British Columbia -- ( BUSINESS WIRE ) -- AbCellera ( Nasdaq : ABCL ) , a technology company with a centralized operating system for next - generation antibody discovery , today announced financial results for the third quarter of 2021. All financial information in this press release is reported in U.S. dollars , unless otherwise indicated . ● " We continue to execute on our long - term business strategy and have achieved another quarter of strong business development and growth in the key metric of program starts , " said Carl Hansen , Ph.D. , CEO and President of AbCellera . " Our focus remains on the following top priorities : execution of our partnership business , forward integration of the platform to support all antibody drug discovery activities for the submission of an Investigational New Drug application , and investments in data science to increase the speed and scalability of our tech stack . " Q3 2021 Business Summary ● 2215 Yukon St. Vancouver , BC Canada , V5Y OA1 T 1. 604.559.9005 ● abcellera.com ● ● • Started discovery on nine programs , bringing the cumulative number of program starts to 69 . Confirmed one new molecule advanced into the clinic , bringing the cumulative total to five . Acquired Tetra Genetics to expand capabilities for high - value transmembrane protein targets . Earned $ 5.5 million in total revenue . Incurred net loss of $ 21.4 million , compared to a net loss of $ 2.7 million in Q3 2020 . Added 17 programs under contract and two new partners , resulting in a cumulative total of 155 programs under contract with 35 different partners . 1